Ixazomib-Based Maintenance Therapy Improves Prognosis of Patients with Multiple Myeloma: A Real-World Study

被引：0
|
作者：
Hong, Xiuli [1 ]
Chen, Jie [1 ]
Lu, Jingyuan [1 ]
Lu, Quanyi [1 ]
机构：
[1] Xiamen Univ, Zhongshan Hosp, Sch Med, Dept Hemotol, Xiamen, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-201297
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7014 / 7015
页数：2
相关论文
共 50 条
  • [1] Ixazomib-Based Maintenance Therapy in Multiple Myeloma Patients Eligible and Ineligible for Transplantation: A Real-World Study (INFINITE Study)
    Fu, Chengcheng
    Jin, Song
    Zhuang, Junling
    Zhou, Xin
    Zhou, Fan
    Li, Yuhua
    Ding, Kaiyang
    Niu, Ting
    Chen, Wenming
    Fang, Baijun
    Chen, Lili
    Fu, Rong
    Zhang, Hao
    Fu, Jiaping
    Wang, Xiuju
    Liu, Sha
    Li, Lin
    Wu, Depei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S226 - S227
  • [2] Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study
    Shen, Man
    Zhang, Jiajia
    Tang, Ran
    Wang, Yuhao
    Zhan, Xiaokai
    Fan, Sibin
    Huang, Zhongxia
    Zhong, Yuping
    Li, Xin
    CANCER MEDICINE, 2022, 11 (11): : 2173 - 2183
  • [3] Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice
    Zhong, Liye
    Wei, Yongqiang
    Ping, Baohong
    Li, Xin
    Peng, Hongling
    Li, Yongqain
    Tian, Yuyang
    Liu, Zelin
    Luo, Jun
    Su, Yongzhong
    Chen, Haifei
    He, Yanjuan
    Li, Hongliang
    Wu, Congming
    Sun, Zhiqiang
    Shi, Keqian
    Li, Xiaoliang
    Zhang, Qing
    Hu, Guoyu
    Huang, Gang
    Huang, Zhenqian
    Wang, Weida
    Xia, Zhongjun
    BLOOD, 2021, 138
  • [4] Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China
    Ding, Kai
    Yu, Hong
    Shao, Yuan-Yuan
    Li, Li-Yan
    Wang, Chao-Meng
    Song, Jia
    Li, Li-Juan
    Fu, Rong
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 8935 - 8941
  • [5] Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study
    Bao, Li
    Wang, Yu -Tong
    Liu, Peng
    Lu, Min-Qiu
    Zhuang, Jun -Ling
    Zhang, Mei
    Xia, Zhong-Jun
    Li, Zhen-Ling
    Yang, Ying
    Yan, Zhen-Yu
    Jing, Hong-Mei
    Dong, Fei
    Chen, Wen -Ming
    Wu, Yin
    Zhou, He -Bing
    Fu, Rong
    Gong, Yu -Ping
    Huang, Wen-Rong
    Zhang, Yong-Qing
    ECLINICALMEDICINE, 2024, 68
  • [6] Proteasome inhibition prolonged by in-class transitioned ixazomib-based regimen in newly diagnosed and first-line relapsed multiple myeloma patients in China: a real-world study
    Liu, Aijun
    Fu, Rong
    Zhu, Zunmin
    Zhuang, Junling
    Bao, Li
    Li, Zhenling
    Da, Gao
    Hua, Luoming
    Liu, Lihong
    Chen, Wenming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S177 - S177
  • [7] Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
    Cohen, Yael C.
    Magen, Hila
    Lavi, Noa
    Gatt, Moshe E.
    Chubar, Evgeni
    Horowitz, Nethanel
    Kreiniz, Natalia
    Tadmor, Tamar
    Trestman, Svetlana
    Vitkon, Roy
    Rouvio, Ory
    Shvetz, Olga
    Shaulov, Adir
    Ziv-Baran, Tomer
    Avivi, Irit
    ANNALS OF HEMATOLOGY, 2020, 99 (06) : 1273 - 1281
  • [8] Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
    Yael C. Cohen
    Hila Magen
    Noa Lavi
    Moshe E. Gatt
    Evgeni Chubar
    Nethanel Horowitz
    Natalia Kreiniz
    Tamar Tadmor
    Svetlana Trestman
    Roy Vitkon
    Ory Rouvio
    Olga Shvetz
    Adir Shaulov
    Tomer Ziv-Baran
    Irit Avivi
    Annals of Hematology, 2020, 99 : 1273 - 1281
  • [9] Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study
    Liu, Aijun
    Yu, Hong
    Hou, Rui
    Zhu, Zunmin
    Zhuang, Jun-ling
    Bao, Li
    Li, Zhenling
    Liu, Lihong
    Hua, Luoming
    Ma, Yanping
    Gao, Da
    Jin, Arong
    Suo, Xiaohui
    Yang, Wei
    Bai, Yuansong
    Fu, Rong
    Zheng, Deqiang
    Chen, Wenming
    CANCER MEDICINE, 2024, 13 (09):
  • [10] Ixazomib and lenalidomide maintenance therapy in multiple myeloma
    Ricardo D. Parrondo
    Victoria Alegria
    Vivek Roy
    Taimur Sher
    Asher A. Chanan-Khan
    Sikander Ailawadhi
    Annals of Hematology, 2021, 100 : 851 - 853
12345